This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
XARELTO® (rivaroxaban)
Medical Information
XARELTO - Management of bleeding - ROCKET AF - Nonvalvular atrial fibrillation
Last updated : 08/25/2025
Piccini et al (2014) conducted an analysis of the safety population (those who received ≥1 dose of study drug) within the ROCKET AF trial to determine whether management of bleeding and subsequent outcomes differed between those treated with XARELTO vs those treated with warfarin.1
Major bleeding: Among the 14,143 randomized patients, 779 (5.5%) experienced major bleeding (XARELTO, n=395; warfarin, n=384).1
The most common products administered for transfusions within 5 days of the major bleed were1:
Whole blood cells, platelets, and cryoprecipitate were also transfused.1
The most common agents used for pharmacologic management after major bleed at 0-24 hours included1:
Outcomes following ISTH major bleeding1
CNS, central nervous system; FFP, fresh frozen plasma; ISTH, International Society on Thrombosis and Haemostasis; MI, myocardial infarction; PCC, prothrombin complex concentrate; PRBC, packed red blood cell; UA, unstable angina.
Reference
Show Hide
1. Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35(28):1873-1880.
